Drug Approval | April 28, 2026
AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease
The submission is backed by positive results from the Phase 3 AFFIRM study
The submission is backed by positive results from the Phase 3 AFFIRM study
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
Subscribe To Our Newsletter & Stay Updated
